Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more
Pangaea Oncology S.A. (PANG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.060x
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has a cash flow conversion efficiency ratio of -0.060x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.26 Million) by net assets (€21.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pangaea Oncology S.A. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pangaea Oncology S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pangaea Oncology S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manx Financial Group PLC
F:3IM
|
-0.264x |
|
Nuriplan Co. Ltd
KQ:069140
|
0.043x |
|
PesoRama Inc.
PINK:PSSOF
|
0.123x |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
0.022x |
|
Kyoritsu Electric Corporation
MU:KYO
|
N/A |
|
PlumbFast Co. Ltd
KQ:035200
|
0.012x |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
0.030x |
|
Siam Steel Service Center Public Company Limited
BK:SSSC
|
0.050x |
Annual Cash Flow Conversion Efficiency for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Pangaea Oncology S.A. from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €22.84 Million | €-4.57 Million | -0.200x | -56.82% |
| 2023-12-31 | €18.81 Million | €-2.40 Million | -0.127x | +19.97% |
| 2022-12-31 | €23.08 Million | €-3.68 Million | -0.159x | +10.27% |
| 2021-12-31 | €14.09 Million | €-2.50 Million | -0.178x | +20.60% |
| 2020-12-31 | €8.57 Million | €-1.92 Million | -0.224x | +22.45% |
| 2019-12-31 | €8.31 Million | €-2.40 Million | -0.288x | -14.68% |
| 2018-12-31 | €8.62 Million | €-2.17 Million | -0.251x | +80.42% |
| 2017-12-31 | €5.05 Million | €-6.48 Million | -1.284x | -336.22% |
| 2016-12-31 | €6.05 Million | €-1.78 Million | -0.294x | +86.59% |
| 2015-12-31 | €1.05 Million | €-2.31 Million | -2.194x | -88.79% |
| 2014-12-31 | €1.63 Million | €-1.89 Million | -1.162x | -221.80% |
| 2013-12-31 | €1.83 Million | €-659.69K | -0.361x | -- |